Study links patient confidence to Rx adherence

Share this article:
Study links patient confidence to Rx adherence
Study links patient confidence to Rx adherence

Doctors may feel crunched for time, but yet another study has found that making time to establish a relationship with patients, as opposed to just offering condition-management information and medical assessments, is essential to increasing medication adherence. This in turn can pay off by reducing the risk of spin-off conditions that crop up when immediate medical issues are not under control.

The study, supported by Kaiser Permanente of Northern California and published online in the Journal of General Internal Medicine, tracked 1,523 patients with Type-2 diabetes in terms of their adherence to antidepressants between 2006 and 2010.

In short, researchers found that patients were less likely to comply with medication regimens if patients felt like they had no input, did not feel as though they trusted their healthcare provider, and felt the doctor-patient relationship was poor.

Researchers said the results backed previous findings that showed care models with better antidepressant adherence included “frequent contacts, outreach and support by care managers, as well as psychoeducation and care coordination.” This has a direct overlap with a 2012-2013 diabetes study that found a high-touch relationship with diabetes patients resulted in a higher level of adherence.

The Kaiser study is a follow-on to a similar drill-down into cardiometabolic drug adherence rates, but researchers noted that this additional patient group was of note because depression is “an important co-morbidity among adults with diabetes and has been associated with poorer disease self management and greater risk of diabetic complications.”

Researchers also found that when patients are both diabetic and depressed, dementia and mortality risk doubles. This is in addition to upping the likelihood of inactivity, poor diet and smoking among patients by between 30% and 100%.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...